原発性毛様体ジスキネジア（PCD）の世界市場レポート 2025年

原発性毛様体ジスキネジア（PCD）の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR（複合年間成長率）6.8％で6億5,000万米ドルに成長します。予測期間中の成長は、希少呼吸器疾患に対する認識の高まり、遺伝子検査の利用可能性の向上、慢性呼吸器感染症の症例の増加、償還政策の改善、専門診断センターの拡大などに起因すると考えられます。予測期間における主な動向としては、遺伝子配列決定技術の発展、非侵襲的診断ツールの開発、研究開発協力の増加、気道確保装置の革新、画像診断における人工知能の統合などが挙げられます。

遺伝子治療に対する需要の高まりは、原発性毛様体ジスキネジア（PCD）市場の拡大を加速させると予想されます。遺伝子治療は、患者の細胞内の欠陥遺伝子を修正または置換し、病気の治療や予防を行うものです。遺伝子治療の需要が急増している背景には、遺伝子研究の著しい進歩があり、遺伝子障害を分子レベルで標的として修正する、より精密な治療が可能になり、患者の予後が改善したことがあります。特に、原発性毛様体ジスキネジア（PCD）では、呼吸器系の繊毛機能不全の原因となる遺伝子変異を修正するための遺伝子治療が開発されています。この治療法は、正常な繊毛運動を回復させ、粘液クリアランスを強化し、呼吸器感染症を減少させるために、健康な遺伝子を導入することを目的としています。例えば、2023年7月、米国の専門会員組織である米国遺伝子細胞治療学会（ASGCT）は、第II相臨床試験中の遺伝子治療プログラム数が2023年第2四半期までに260に達し、第1四半期から5％増加したと報告しました。このような遺伝子治療への注目の高まりが、原発性毛様体ジスキネジア市場の成長を牽引しています。

原発性毛様体ジスキネジア（PCD）市場の主なプレーヤーは、症状管理を改善し、患者のQOLを高めるために、治験中のmRNAベースの治療法などの革新的な治療法の開発に注力しています。mRNAベースの治療法は、メッセンジャーRNA（mRNA）を使用して、疾患の治療や予防につながるタンパク質の産生を細胞に指示します。この最先端のアプローチは、分子レベルでの病態を標的とし、個別化医療につながります。例えば、2024年6月、米国のバイオテクノロジー企業であるReCode Therapeutics, Inc.は、治験中の吸入mRNA療法であるRCT1100を発売しました。この治療法は、原発性毛様体ジスキネジアの治療薬として米国食品医薬品局（FDA）から希少疾病用医薬品の指定を受けた。RCT1100は、DNAI1 mRNAを気道細胞に直接送達することにより毛様体機能を回復させることを目的としており、米国においてPCDに罹患していると推定される4万5,000人の患者にとって、この疾患に対する疾患修飾治療や治療法が存在しないことから、重要なアンメットニーズに応えるものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の原発性毛様体ジスキネジア（PCD） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の原発性毛様体ジスキネジア（PCD）市場：成長率分析
• 世界の原発性毛様体ジスキネジア（PCD）市場の実績：規模と成長, 2019-2024
• 世界の原発性毛様体ジスキネジア（PCD）市場の予測：規模と成長, 2024-2029, 2034F
• 世界の原発性毛様体ジスキネジア（PCD）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の原発性毛様体ジスキネジア（PCD）市場：治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗生物質
• 気道クリアランス療法
• 外科的介入
• その他の治療法
• 世界の原発性毛様体ジスキネジア（PCD）市場：方法別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遺伝子検査
• 画像技術
• 臨床評価
• 肺機能検査
• 世界の原発性毛様体ジスキネジア（PCD）市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 直接販売
• オンライン薬局
• サードパーティの販売業者
• 小売薬局
• 世界の原発性毛様体ジスキネジア（PCD）市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 診断検査室
• その他のエンドユーザー
• 世界の原発性毛様体ジスキネジア（PCD）市場、抗生物質、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• マクロライド
• ペニシリン
• セファロスポリン
• フルオロキノロン
• アミノグリコシド
• 世界の原発性毛様体ジスキネジア（PCD）市場、気道クリアランス療法、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• 胸部理学療法
• 高周波胸壁振動（HFCWO）
• 呼気陽圧（PEP）療法
• 肺内パーカッション換気（IPV）
• 振動性呼気陽圧（OPEP）
• 世界の原発性毛様体ジスキネジア（PCD）市場、外科的介入、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• 副鼻腔手術
• 鼓室チューブの配置
• 肺移植
• 世界の原発性毛様体ジスキネジア（PCD）市場、その他の治療法、タイプ別サブセグメンテーション：実績と予測, 2019-2024, 2024-2029F, 2034F
• 粘液溶解薬
• 免疫調節療法
• 遺伝子治療
• 幹細胞療法

第7章 地域別・国別分析

• 世界の原発性毛様体ジスキネジア（PCD）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の原発性毛様体ジスキネジア（PCD）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 原発性毛様体ジスキネジア（PCD）市場：競合情勢
• 原発性毛様体ジスキネジア（PCD）市場：企業プロファイル
  • Centogene N.V. Overview, Products and Services, Strategy and Financial Analysis
  • Nationwide Children's Hospital Overview, Products and Services, Strategy and Financial Analysis
  • Revvity Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Quest Diagnostics Incorporated Overview, Products and Services, Strategy and Financial Analysis
  • Children's Healthcare of Atlanta Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Exact Sciences Corp.
• University Hospital Southampton
• UT Health East Texas
• Guy's and St Thomas'NHS Foundation Trust
• National Jewish Health
• Vanderbilt University Medical Center
• UNC School of Medicine
• Stanford Medicine
• Mayo Foundation for Medical Education and Research
• DNA Labs India Pvt. Ltd.
• Parion Sciences Inc.
• ReCode Therapeutics Inc.
• University Hospital Munster
• UAB Health System
• PCD Foundation

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 原発性毛様体ジスキネジア（PCD）市場2029：新たな機会を提供する国
• 原発性毛様体ジスキネジア（PCD）市場2029：新たな機会を提供するセグメント
• 原発性毛様体ジスキネジア（PCD）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Primary ciliary dyskinesia (PCD) is a rare inherited disorder that affects the normal function and structure of cilia, which are microscopic, hair-like structures found in the airways, ears, and reproductive tract. Understanding and diagnosing PCD is essential for managing symptoms early and improving quality of life through targeted therapies.

The main types of treatment for primary ciliary dyskinesia (PCD) include antibiotics, airway clearance therapies, surgical interventions, and other supportive therapies. Antibiotics help treat respiratory bacterial infections, prevent lung damage, and maintain airway health. PCD is diagnosed through various methods, such as genetic testing, imaging techniques, clinical evaluation, and lung function tests. The treatments are distributed through multiple channels, including direct sales, online pharmacies, third-party distributors, and retail pharmacies. End-users of PCD treatments include hospitals, specialty clinics, diagnostic laboratories, and other healthcare providers.

The primary ciliary dyskinesia (PCD) market research report is one of a series of new reports from The Business Research Company that provides primary ciliary dyskinesia (PCD) market statistics, including the primary ciliary dyskinesia (PCD) industry global market size, regional shares, competitors with the primary ciliary dyskinesia (PCD) market share, detailed primary ciliary dyskinesia (PCD) market segments, market trends, opportunities, and any further data you may need to thrive in the primary ciliary dyskinesia (PCD) industry. This primary ciliary dyskinesia (PCD) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The primary ciliary dyskinesia market size has grown strongly in recent years. It will grow from $0.46 billion in 2024 to $0.50 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth during the historic period can be attributed to increasing clinical confusion with other respiratory disorders, a greater reliance on symptomatic treatment, enhanced use of general respiratory therapies, expanded diagnosis based on exclusion methods, and a growing focus on cystic fibrosis, which often overshadowed primary ciliary dyskinesia.

The primary ciliary dyskinesia market size is expected to see strong growth in the next few years. It will grow to $0.65 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth during the forecast period can be attributed to growing awareness of rare respiratory diseases, improved availability of genetic testing, a rise in cases of chronic respiratory infections, better reimbursement policies, and the expansion of specialized diagnostic centers. Key trends in the forecast period include advancements in genetic sequencing technologies, the development of non-invasive diagnostic tools, increased research and development collaborations, innovations in airway clearance devices, and the integration of artificial intelligence in diagnostic imaging.

The growing demand for gene therapy is expected to accelerate the expansion of the primary ciliary dyskinesia (PCD) market. Gene therapy involves modifying or replacing faulty genes in a patient's cells to treat or prevent diseases. The demand for gene therapy has surged due to significant progress in genetic research, allowing for more precise treatments that target and correct genetic disorders at the molecular level, improving patient outcomes. In particular, gene therapy is being developed for Primary Ciliary Dyskinesia (PCD) to correct the genetic mutations responsible for defective cilia function in the respiratory system. This therapy aims to introduce healthy genes to restore normal ciliary movement, enhance mucus clearance, and reduce respiratory infections. For example, in July 2023, the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, reported that the number of gene therapy programs in Phase II clinical trials reached 260 by the second quarter of 2023, a 5% increase from the first quarter. This growing focus on gene therapy is driving the growth of the primary ciliary dyskinesia market.

Key players in the primary ciliary dyskinesia market are focusing on the development of innovative therapies, such as investigational mRNA-based treatments, to improve symptom management and enhance the quality of life for patients. mRNA-based therapeutics use messenger RNA (mRNA) to instruct cells to produce proteins that may treat or prevent diseases. This cutting-edge approach targets conditions at the molecular level, leading to personalized medicine. For instance, in June 2024, ReCode Therapeutics, Inc., a US-based biotechnology company, launched RCT1100, an investigational inhaled mRNA therapy. The therapy received orphan drug designation from the U.S. Food and Drug Administration (FDA) for treating primary ciliary dyskinesia. RCT1100 aims to restore ciliary function by delivering DNAI1 mRNA directly to airway cells, addressing a critical unmet need for the estimated 45,000 individuals affected by PCD in the U.S., as there are currently no disease-modifying treatments or cures for this condition.

In October 2024, PCD Research, a UK-based charitable organization focused on primary ciliary dyskinesia research, partnered with the Nucleic Acid Therapy Accelerator (NATA) to advance therapies for primary ciliary dyskinesia. The collaboration aims to co-fund a grant dedicated to developing innovative treatments for PCD, a rare genetic disorder that impairs respiratory function. The partnership seeks to support groundbreaking research that will improve treatment options and outcomes for individuals affected by this progressive and debilitating condition. NATA is a UK-based research initiative specializing in nucleic acid therapeutics.

Major players in the primary ciliary dyskinesia (pcd) market are Centogene N.V., Nationwide Children's Hospital, Revvity Inc., Quest Diagnostics Incorporated, Children's Healthcare of Atlanta, Exact Sciences Corp., University Hospital Southampton, UT Health East Texas, Guy's and St Thomas' NHS Foundation Trust, National Jewish Health, Vanderbilt University Medical Center, UNC School of Medicine, Stanford Medicine, Mayo Foundation for Medical Education and Research, DNA Labs India Pvt. Ltd., Parion Sciences Inc., ReCode Therapeutics Inc., University Hospital Munster, UAB Health System, PCD Foundation.

North America was the largest region in the primary ciliary dyskinesia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in primary ciliary dyskinesia (PCD) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the primary ciliary dyskinesia (PCD) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary ciliary dyskinesia market consists of revenues earned by entities by providing services such as pulmonary rehabilitation, home healthcare services, and genetic counselling. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary ciliary dyskinesia market includes sales of immunofluorescence microscopy, transmission electron tomography, and whole-exome sequencing kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified.)

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Primary Ciliary Dyskinesia (PCD) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on primary ciliary dyskinesia (pcd) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for primary ciliary dyskinesia (pcd) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The primary ciliary dyskinesia (pcd) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Antibiotics; Airway Clearance Therapies; Surgical Interventions; Other Treatments
• 2) By Method: Genetic Testing; Imaging Techniques; Clinical Evaluation; Lung Function Tests
• 4) By Distribution Channel: Direct Sales; Online Pharmacies; Third-party Distributors; Retail Pharmacies
• 4) By End-User: Hospitals; Specialty Clinics; Diagnostic Laboratories; Other End-Users
• Subsegments:
• 1) By Antibiotics: Macrolides; Penicillins; Cephalosporins; Fluoroquinolones; Aminoglycosides
• 2) By Airway Clearance Therapies: Chest Physiotherapy; High-Frequency Chest Wall Oscillation (HFCWO); Positive Expiratory Pressure (PEP) Therapy; Intrapulmonary Percussive Ventilation (IPV); Oscillatory Positive Expiratory Pressure (OPEP)
• 3) By Surgical Interventions: Sinus Surgery; Tympanostomy Tube Placement; Lung Transplantation
• 4) By Other Treatments: Mucolytics; Immunomodulatory Therapies; Gene Therapy; Stem Cell Therapy
• Companies Mentioned: Centogene N.V.; Nationwide Children's Hospital; Revvity Inc.; Quest Diagnostics Incorporated; Children's Healthcare of Atlanta
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Primary Ciliary Dyskinesia (PCD) Market Characteristics

3. Primary Ciliary Dyskinesia (PCD) Market Trends And Strategies

4. Primary Ciliary Dyskinesia (PCD) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Primary Ciliary Dyskinesia (PCD) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Primary Ciliary Dyskinesia (PCD) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Primary Ciliary Dyskinesia (PCD) Market Growth Rate Analysis
• 5.4. Global Primary Ciliary Dyskinesia (PCD) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Primary Ciliary Dyskinesia (PCD) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Primary Ciliary Dyskinesia (PCD) Total Addressable Market (TAM)

6. Primary Ciliary Dyskinesia (PCD) Market Segmentation

• 6.1. Global Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antibiotics
• Airway Clearance Therapies
• Surgical Interventions
• Other Treatments
• 6.2. Global Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genetic Testing
• Imaging Techniques
• Clinical Evaluation
• Lung Function Tests
• 6.3. Global Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Direct Sales
• Online Pharmacies
• Third-party Distributors
• Retail Pharmacies
• 6.4. Global Primary Ciliary Dyskinesia (PCD) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Diagnostic Laboratories
• Other End-Users
• 6.5. Global Primary Ciliary Dyskinesia (PCD) Market, Sub-Segmentation Of Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Macrolides
• Penicillins
• Cephalosporins
• Fluoroquinolones
• Aminoglycosides
• 6.6. Global Primary Ciliary Dyskinesia (PCD) Market, Sub-Segmentation Of Airway Clearance Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chest Physiotherapy
• High-Frequency Chest Wall Oscillation (HFCWO)
• Positive Expiratory Pressure (PEP) Therapy
• Intrapulmonary Percussive Ventilation (IPV)
• Oscillatory Positive Expiratory Pressure (OPEP)
• 6.7. Global Primary Ciliary Dyskinesia (PCD) Market, Sub-Segmentation Of Surgical Interventions, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sinus Surgery
• Tympanostomy Tube Placement
• Lung Transplantation
• 6.8. Global Primary Ciliary Dyskinesia (PCD) Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mucolytics
• Immunomodulatory Therapies
• Gene Therapy
• Stem Cell Therapy

7. Primary Ciliary Dyskinesia (PCD) Market Regional And Country Analysis

• 7.1. Global Primary Ciliary Dyskinesia (PCD) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Primary Ciliary Dyskinesia (PCD) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Primary Ciliary Dyskinesia (PCD) Market

• 8.1. Asia-Pacific Primary Ciliary Dyskinesia (PCD) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Primary Ciliary Dyskinesia (PCD) Market

• 9.1. China Primary Ciliary Dyskinesia (PCD) Market Overview
• 9.2. China Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Primary Ciliary Dyskinesia (PCD) Market

• 10.1. India Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Primary Ciliary Dyskinesia (PCD) Market

• 11.1. Japan Primary Ciliary Dyskinesia (PCD) Market Overview
• 11.2. Japan Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Primary Ciliary Dyskinesia (PCD) Market

• 12.1. Australia Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Primary Ciliary Dyskinesia (PCD) Market

• 13.1. Indonesia Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Primary Ciliary Dyskinesia (PCD) Market

• 14.1. South Korea Primary Ciliary Dyskinesia (PCD) Market Overview
• 14.2. South Korea Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Primary Ciliary Dyskinesia (PCD) Market

• 15.1. Western Europe Primary Ciliary Dyskinesia (PCD) Market Overview
• 15.2. Western Europe Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Primary Ciliary Dyskinesia (PCD) Market

• 16.1. UK Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Primary Ciliary Dyskinesia (PCD) Market

• 17.1. Germany Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Primary Ciliary Dyskinesia (PCD) Market

• 18.1. France Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Primary Ciliary Dyskinesia (PCD) Market

• 19.1. Italy Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Primary Ciliary Dyskinesia (PCD) Market

• 20.1. Spain Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Primary Ciliary Dyskinesia (PCD) Market

• 21.1. Eastern Europe Primary Ciliary Dyskinesia (PCD) Market Overview
• 21.2. Eastern Europe Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Primary Ciliary Dyskinesia (PCD) Market

• 22.1. Russia Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Primary Ciliary Dyskinesia (PCD) Market

• 23.1. North America Primary Ciliary Dyskinesia (PCD) Market Overview
• 23.2. North America Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Primary Ciliary Dyskinesia (PCD) Market

• 24.1. USA Primary Ciliary Dyskinesia (PCD) Market Overview
• 24.2. USA Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Primary Ciliary Dyskinesia (PCD) Market

• 25.1. Canada Primary Ciliary Dyskinesia (PCD) Market Overview
• 25.2. Canada Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Primary Ciliary Dyskinesia (PCD) Market

• 26.1. South America Primary Ciliary Dyskinesia (PCD) Market Overview
• 26.2. South America Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Primary Ciliary Dyskinesia (PCD) Market

• 27.1. Brazil Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Primary Ciliary Dyskinesia (PCD) Market

• 28.1. Middle East Primary Ciliary Dyskinesia (PCD) Market Overview
• 28.2. Middle East Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Primary Ciliary Dyskinesia (PCD) Market

• 29.1. Africa Primary Ciliary Dyskinesia (PCD) Market Overview
• 29.2. Africa Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Primary Ciliary Dyskinesia (PCD) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Primary Ciliary Dyskinesia (PCD) Market Competitive Landscape And Company Profiles

• 30.1. Primary Ciliary Dyskinesia (PCD) Market Competitive Landscape
• 30.2. Primary Ciliary Dyskinesia (PCD) Market Company Profiles
  • 30.2.1. Centogene N.V. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Nationwide Children's Hospital Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Revvity Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Quest Diagnostics Incorporated Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Children's Healthcare of Atlanta Overview, Products and Services, Strategy and Financial Analysis

31. Primary Ciliary Dyskinesia (PCD) Market Other Major And Innovative Companies

• 31.1. Exact Sciences Corp.
• 31.2. University Hospital Southampton
• 31.3. UT Health East Texas
• 31.4. Guy's and St Thomas' NHS Foundation Trust
• 31.5. National Jewish Health
• 31.6. Vanderbilt University Medical Center
• 31.7. UNC School of Medicine
• 31.8. Stanford Medicine
• 31.9. Mayo Foundation for Medical Education and Research
• 31.10. DNA Labs India Pvt. Ltd.
• 31.11. Parion Sciences Inc.
• 31.12. ReCode Therapeutics Inc.
• 31.13. University Hospital Munster
• 31.14. UAB Health System
• 31.15. PCD Foundation

32. Global Primary Ciliary Dyskinesia (PCD) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Primary Ciliary Dyskinesia (PCD) Market

34. Recent Developments In The Primary Ciliary Dyskinesia (PCD) Market

35. Primary Ciliary Dyskinesia (PCD) Market High Potential Countries, Segments and Strategies

• 35.1 Primary Ciliary Dyskinesia (PCD) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Primary Ciliary Dyskinesia (PCD) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Primary Ciliary Dyskinesia (PCD) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer